Muscular dystrophy refers to a group of genetic diseases that cause progressive weakness and loss of muscle mass. While there is currently no cure for muscular dystrophy, significant progress has been made in recent decades to improve treatment options and quality of life for those living with these conditions. This article will explore some of the most promising advancements in muscular dystrophy treatment.
Gene Therapy
Gene therapy involves introducing normal copies of genes into muscles in an attempt to compensate for mutated, non-functioning genes that cause muscular dystrophy. Several gene therapy clinical trials have shown early promise for treating certain types of muscular dystrophy. For example, a phase I/II clinical trial of gene therapy in 12 patients with Duchenne muscular dystrophy saw significant improvements in strength and function after two years. Researchers were able to deliver a functional copy of the dystrophin gene to skeletal muscles using an adeno-associated viral vector. Ongoing research aims to further refine gene therapy techniques and protocols to treat more muscles more safely and effectively.
Stem Cell Therapy
Stem cell therapies for muscular dystrophy seek to replace damaged muscle cells by transplanting healthy stem cells which can then differentiate into new muscle fibers. In 2018, the very first clinical trial of stem cell therapy for Duchenne muscular dystrophy showed transplantation of muscle-derived stem cells led to modest increases in strength and function over 18 months with no significant safety issues reported. Multiple other stem cell clinical trials are ongoing to evaluate different cell types and transplantation methods. While stem cell therapy remains experimental, it offers hope that one day cells could be used to continuously regenerate and repair degenerating muscles.
Exon Skipping
Exon skipping aims to partially fix genetic mutations causing muscular dystrophy by modifying pre-mRNA splicing so that certain exons are skipped during gene transcription. This can produce an abbreviated, yet still functional version of the target protein like dystrophin. The first exon skipping drug eteplirsen was approved by the FDA in 2016 for Duchenne muscular dystrophy. In clinical trials, eteplirsen achieved significant increases in dystrophin production levels and stabilized or improved motor function. Additional exon skipping drugs continue entering clinical trials with the goal of developing personalized therapies tailored to individual patients’ mutations.
Assistive Devices and Adaptations
While not directly treating the underlying disease, assistive devices and home/vehicle adaptations can help preserve independence and improve quality of life for those with muscular dystrophy. For instance, leg braces, wheelchairs, mobility scooters, lifts, and ramps allow for easier mobility and accessibility. Adaptive devices like computer access technologies, environmental controls, and communication aids empower individuals to participate more fully in school, work, and activities of daily living for as long as possible. Regular physical and occupational therapy can teach muscle-strengthening and energy-saving techniques to perform tasks safely and comfortably with the aid of customized equipment.
Multidisciplinary Care
Due to various systemic effects, people with muscular dystrophy often require a coordinated team of specialists. In addition to neurologists and geneticists, input from cardiologists, pulmonologists, orthopedists, rehabilitation therapists, and social workers can optimize medical management, prevent complications, and provide psychological support. Multidisciplinary clinics centralize care where patients see multiple experts in one visit to efficiently address their diverse needs. Telehealth has also expanded access by enabling remote consultations and monitoring which may be important as disabilities progress over the decades-long course of many muscular dystrophies. A comprehensive care model adopting a holistic, patient-centered approach can help muscular dystrophy patients live as fully as possible.
Nutrition and Exercise
For many years, the standard recommendations for muscular dystrophy treatment focused on limiting physical activity to avoid muscle damage. However, more recent research shows low-impact aerobic exercise and resistance training may actually confer physical and psychological benefits if performed safely under medical guidance. Studies have found water-based exercises like swimming and aquatic therapy to be particularly suitable options. Additionally, maintaining optimal weight, calcium/vitamin D levels, and adequate protein intake is important for bone and muscle health. A balanced, nutritious diet along with modified but regular low-impact physical activity tailored to a patient’s abilities aims to delay disease progression and preserve quality of life.
Overall, while still incurable, muscular dystrophy is nowadays considered a manageable chronic condition rather than a uniformly fatal disease process of the past due to important therapeutic developments. Through continued multidisciplinary care, assistive technologies, lifestyle adaptations, gene/stem cell therapies, exon skipping medications, and participation in carefully monitored exercise/nutrition regimens, individuals with muscular dystrophy are achieving longer, healthier, and fuller lives. With ongoing clinical research and innovation, even more progress can be expected to treat, and hopefully one day cure, these debilitating muscle disorders.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it